Schizas Dimitrios, Moris Demetrios, Michalinos Adamantios, Kanavidis Prodromos, Oikonomou Dimitrios, Papalampros Alexandros, Machairas Anastasios, Liakakos Theodoros
3rd Department of Surgery, "Attikon" General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
J BUON. 2017 Mar-Apr;22(2):383-389.
Gastric cancer (GC) is still one of the most common malignancies with the majority of the tumors being diagnosed at advanced stage. The need for identification of prognostic and early detection biomarkers is thus compulsory. E-cadherin is one of the emerging biomarkers that is currently evaluated in the literature in the frame of epithelial-mesenchymal transition (EMT). Our aim was to study the expression of E-cadherin in the various histological subtypes of GC and to evaluate its prognostic value.
This historical cohort survey was performed on gastric tumors obtained from 66 (46 men and 20 women) patients with documented gastric adenocarcinoma who underwent total or partial gastrectomy and regional lymphadenectomy from 2003 till 2011. Features such as tumor size, depth of invasion, grade and histological subtype, lymphovascular space invasion and regional lymph nodes involvement were also evaluated. Immunohistochemistry (IHC) was used for assessing the expression of E-cadherin with a semi-quantitative model.
The correlation of E-cadherin tissue expression with patient overall survival (OS) or disease-free survival (DFS) was not statistically significant, as well as with gender, T stage, N stage, TNM stage, grade, positive lymph nodes ratio or lymphovascular invasion.
73.0% of the evaluated tumors showed abnormal E-cadherin expression in IHC, but the correlation of E-cadherin tissue expression with patient OS or DFS was not statistically significant. Literature stands equivocal about the association between E-cadherin gene mutation, and histopathology and tumor invasiveness. Our results further strengthen the need of larger studies to fully elucidate the predictive role of E-cadherin in the natural history of GC.
胃癌（GC）仍是最常见的恶性肿瘤之一，大多数肿瘤在晚期才被诊断出来。因此，识别预后和早期检测生物标志物是必不可少的。E-钙黏蛋白是目前在文献中作为上皮-间质转化（EMT）框架下进行评估的新兴生物标志物之一。我们的目的是研究E-钙黏蛋白在胃癌各种组织学亚型中的表达，并评估其预后价值。
本回顾性队列研究对2003年至2011年期间接受全胃或部分胃切除术及区域淋巴结清扫术的66例（46例男性和20例女性）有记录的胃腺癌患者的胃肿瘤进行了研究。还评估了肿瘤大小、浸润深度、分级和组织学亚型、淋巴管间隙浸润和区域淋巴结受累等特征。采用免疫组织化学（IHC）以半定量模型评估E-钙黏蛋白的表达。
E-钙黏蛋白组织表达与患者总生存期（OS）或无病生存期（DFS）的相关性无统计学意义，与性别、T分期、N分期、TNM分期、分级、阳性淋巴结比例或淋巴管浸润也无相关性。
73.0%的评估肿瘤在免疫组织化学中显示E-钙黏蛋白表达异常，但E-钙黏蛋白组织表达与患者OS或DFS的相关性无统计学意义。关于E-钙黏蛋白基因突变与组织病理学及肿瘤侵袭性之间的关联，文献尚无定论。我们的结果进一步强调需要进行更大规模的研究，以充分阐明E-钙黏蛋白在胃癌自然病程中的预测作用。
